Phase 1B Clinical Trial Studying the Safety, Activity, and Effectiveness of Cevostamab in Treating People with Relapsed or Refractory Multiple Myeloma

What's the purpose of the trial?

The goal of this clinical trial is to learn how well cevostamab works and how safe it is when used by itself or when used in combination with other medicines to treat people with relapsed or refractory multiple myeloma.

Researchers in this clinical trial are looking to enroll approximately 120 people with relapsed or refractory multiple myeloma who have previously been treated for their disease with at least one other medicine.  People participating in this trial will be divided into three different groups. Group A will receive cevostamab as their only treatment (also called cevostamab monotherapy).  Group B will receive cevostamab in addition to two other medicines - pomalidomide and dexamethasone.  And Group C will receive cevostamab in addition to daratumumab and dexamethasone.  Additional information about when and how each group will receive their treatment is provided below.  

In addition to splitting participants into different treatment groups (also known as treatment arms), this clinical trial will take a phased approach to enrollment.  Each treatment arm will first include approximately 6 patients. When these people have completed 1 full cycle of treatment, and if there are no safety concerns, an additional 30 people will be enrolled into the treatment arm. Researchers are taking this approach because this is an early trial of cevostamab, which is an investigational medicine, and it is important that there is a close follow-up to ensure treatment safety.  

 All participants will need to be hospitalized for approximately 48 hours while receiving their first two or three doses of Cevostamab. Specific hospitalization requirements will depend on which group patients participate in. 

Trial status

Not currently accepting

Phase 1
Last Updated
3 weeks ago
Am I Eligible

Participating Centers

There are 3 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Cevostamab is a bispecific T-cell engager antibody that targets both FCRH5 found on cancer cells and CD3 antigen found on T lymphocytes.
  • Daratumumab is a type of cancer drug called a monoclonal antibody. Daratumumab attaches to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
  • Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
  • Pomalidomide is a kind of medication called an immunomodulatory agent that promotes an immune response to help slow tumor growth. Pomalidomide is used in the treatment of several different indications.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.